The solid cancer targeting technology of Albatroz Therapeutics has been featured in A * STAR Research Highlights.
The therapeutic approach is based on the novel discovery by the A * STAR lab of Abatroz’s scientific founder Dr. Frederic Bard that glycosylation-driven extracellular matrix degradation is essential for tumor growth.
Menu